SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Hyundai Mobis, a leading global automotive supplier, will unveil its vision for the future of mobility at CES 2025, taking place at the Las Vegas Convention Center from January 7-10, 2025.
At CES, the company will unveil its Holographic Windshield Display, a groundbreaking innovation that enhances driving visibility through augmented reality. This first-of-its-kind display projects critical driving information—such as navigation, infotainment, and safety alerts—across the entire width of the front windshield. The result is a panoramic and immersive experience that seamlessly spans from the driver's seat to the passenger's seat.
Co-developed with the leading German optics company ZEISS, the display will be featured in Kia's electric vehicle, the EV9, exclusively for its unveiling at CES. By integrating specialized optical film, the system provides easy access to key information while maintaining an open, spacious feel and improving overall driving safety. Hyundai Mobis plans to begin mass production of this advanced technology as early as 2027.
Under the theme "Beyond and More," Hyundai Mobis will showcase a unique user experience at CES through its "Human Tech" initiative—a suite of technologies designed to bridge the gap between people and technology while enhancing safety and convenience with seamless, adaptive connections. Alongside the holographic windshield display, the company will unveil a human-centric interior lighting system that intelligently adapts to user needs and M.Brain, an advanced brainwave-based system that monitors and addresses driver distractions.
Hyundai Mobis will unveil its Human-Centric Interior Lighting technology, an adaptive lighting solution designed to adjust to the user's mood and environment. This innovative system offers 32 situational modes, including features to reduce driver stress, alleviate motion sickness, prevent dismounting hazards, and even provide UV-C sterilization. Visitors to the Hyundai Mobis booth can experience firsthand how this advanced lighting technology dynamically responds to biological rhythms, health conditions, and the vehicle's surroundings.
Another standout innovation is M.Brain, Hyundai Mobis' flagship brainwave-based technology. This advanced system monitors driver focus in real-time by analyzing brainwave data, providing alerts during states of drowsiness or inattention. Live demonstrations at CES will give visitors the opportunity to see M.Brain in action and explore its potential to enhance driver safety.
CES 2025 will mark Hyundai Mobis' tenth consecutive appearance at the world's largest tech show. Over the years, the company has consistently highlighted groundbreaking mobility innovations and production-ready technologies. At CES 2025, Hyundai Mobis will reaffirm its position as a leader in shaping the future of mobility.
About Mobis
Hyundai Mobis is the global no. 6 automotive supplier, headquartered in Seoul, Korea. Mobis has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company's products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics. Mobis operates its R&D headquarters in Korea, with four technology centers in the United States, Germany, China and India. For more information, please visit the website at http://www.mobis.com
Media Contact
Choon Kee Hwang
+82-2-2018-5519
ckhwang@mobis.com
Myong Sun Song
+82-2-2018-6535
sms@mobis.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Hyundai Mobis to Showcase World's First Full-Windshield Holographic Display at CES 2025
SEONGNAM, South Korea, Dec. 12, 2024 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced today that it has received approval from the Human Research Ethics Committee (HREC) in Australia for the clinical trial protocols of a Phase 1/2 trials for its mRNA-based Japanese encephalitis vaccine candidate, GBP560.
SK bioscience is establishing its mRNA vaccine platform through the development of vaccines against Japanese encephalitis virus as well as Lassa fever virus.
The Japanese Encephalitis Virus (viral family: Flaviviruses) and Lassa fever vaccines (viral family: Arenaviruses) will serve as prototype vaccines that could potentially be adapted in a matter of weeks for use against a future Disease X that might emerge from those same viral families. This approach is key to the 100 Days Mission, a global goal to accelerate the development of vaccines against pandemic threats to just over three months.
This joint project is based on an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), which committed up to USD 40 million initial funding (approximately KRW 57.4 billion) in funding in 2022 to support preclinical and early clinical trials. A further USD 100 million in funding could be made available at a later date to support late-stage trials/licensure to further validate the mRNA platform and have it ready for use in outbreak situations.
The partnership builds upon SK bioscience's expertise in cutting-edge vaccine platforms such as cell culture, bacterial culture, and recombinant technology. By expanding the company's capabilities to include the mRNA platform, the collaboration aims to be ready to rapidly respond to Disease X and contribute to equitable access to vaccines, including through a contractual commitment to, if successful, prioritize supply for low-and middle-income countries, produce vaccine volumes required to meet public health needs, and ensure affordable pricing.
The mRNA vaccine platform technology, which was first commercialized in the COVID-19 vaccines during the pandemic, is available for rapid mass production compared to traditional platforms by utilizing genetic sequences. This capability makes mRNA technology well-suited for pandemic response. Furthermore, the mRNA vaccine platform shows significant potential to be applied to the development of therapeutic drugs, signaling rapid market expansion.
According to global market research firm 'Nova One Advisor', the global mRNA therapeutics market is projected to surpass around USD 58.90 billion (approximately KRW 84.5 trillion) by 2033, registering a CAGR of 17.06% by 2033.
The company will evaluate the immunogenicity and safety of GBP560 in 402 healthy adult participants in Australia. In stage 1, the participants will receive two shots of low, medium, high-dose vaccine, or a control vaccine administered 28 days apart. Based on the stage 1 results, the optimal dosage and regimen will be determined for further assessment of the immunogenicity and safety compared to the control group in stage 2.
During the Phase 1/2 trials, SK bioscience plans to confirm neutralizing antibody titers and immune responses, along with collecting data on major adverse events, safety indicators, and the rate of adverse reactions. The company aims to secure interim results by 2026.
Previously, the company conducted preclinical studies beginning in December 2023, where the vaccine candidate demonstrated superior safety and immunogenicity through repeated-dose toxicity studies, safety pharmacology tests, animal efficacy trials, and protective immunity tests.
Dr. Kent Kester, Executive Director of Vaccine Research and Development at CEPI said, "mRNA technology is at the heart of CEPI's work to build a library of vaccine candidates that could be swiftly adapted next time Disease X emerges. Our work with SK bioscience aims to validate the rapid response mRNA platform against viruses from two of the viral families with the potential to spawn future epidemics and pandemics, contributing to the 100 Days Mission and to building a safer world for all."
Jaeyong Ahn, CEO of SK bioscience, said, "The mRNA vaccine platform, with its rapid development cycle, is a critical tool for pandemic preparedness. By leveraging our strong network of various partners, including international organizations, global companies, and the Korean government, SK bioscience is committed to successfully establishing the mRNA technology platform and contributing to global health, equitable access to vaccines and vaccine sovereignty."
CEPI also supported the development of SK bioscience's COVID-19 vaccine and is funding an ongoing project to support a broadly protective coronavirus vaccine.
About SK bioscience
SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.
- SK bioscience Website
- SK bioscience Linkedin
Contact
Communications Team
Changhyun Jin (jin99@sk.com), Jeannie S. Pak (j.pak@sk.com)
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
